title: RECQ helicases are deregulated in hematological malignancies in association with a prognostic value.
abstract: BACKGROUND
  RECQ helicase family members act as guardians of the genome to assure proper DNA metabolism in response to genotoxic stress. Hematological malignancies are characterized by genomic instability that is possibly related to underlying defects in DNA repair of genomic stability maintenance.
  
  
  METHODS
  We have investigated the expression of RECQ helicases in different hematological malignancies and in their normal counterparts using publicly available gene expression data. Furthermore, we explored whether RECQ helicases expression could be associated with tumor progression and prognosis.
  
  
  RESULTS
  Expression of at least one RECQ helicase family member was found significantly deregulated in all hematological malignancies investigated when compared to their normal counterparts. In addition, RECQ helicase expression was associated with a prognostic value in acute myeloid leukemia, chronic lymphocytic leukemia, lymphoma and multiple myeloma.
  
  
  CONCLUSIONS
  RECQ helicase expression is deregulated in hematological malignancies compared to their normal counterparts in association with a prognostic value. Deregulation of RECQ helicases appears to play a role in tumorigenesis and represent potent therapeutic targets for synthetic lethal approaches in hematological malignancies.
authors.affiliation: Institute of Human Genetics, CNRS-UPR1142, Montpellier, F-34396 France.
authors.forename: Elena
authors.initials: E
authors.lastname: Viziteu
authors.affiliation: Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, Hôpital Saint-Eloi - CHRU de Montpellier, 80, av. Augustin Fliche, 34295 Montpellier, Cedex 5 France ; Institute of Human Genetics, CNRS-UPR1142, Montpellier, F-34396 France.
authors.forename: Alboukadel
authors.initials: A
authors.lastname: Kassambara
authors.affiliation: Institute of Human Genetics, CNRS-UPR1142, Montpellier, F-34396 France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Pasero
authors.affiliation: Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, Hôpital Saint-Eloi - CHRU de Montpellier, 80, av. Augustin Fliche, 34295 Montpellier, Cedex 5 France ; Institute of Human Genetics, CNRS-UPR1142, Montpellier, F-34396 France ; University of Montpellier 1, UFR de Médecine, Montpellier, France.
authors.forename: Bernard
authors.initials: B
authors.lastname: Klein
authors.affiliation: Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, Hôpital Saint-Eloi - CHRU de Montpellier, 80, av. Augustin Fliche, 34295 Montpellier, Cedex 5 France ; Institute of Human Genetics, CNRS-UPR1142, Montpellier, F-34396 France ; University of Montpellier 1, UFR de Médecine, Montpellier, France.
authors.forename: Jerome
authors.identifier: 0000-0002-5717-3207
authors.initials: J
authors.lastname: Moreaux
keywords: Gene expression; Hematological malignancies; Prognostic markers; RECQ helicases; Therapeutic targets